中国药房2017，Vol.28Issue(4)：455-457,3.DOI:10.6039/j.issn.1001-0408.2017.04.06
我国创新药进入医保目录的障碍与对策
Barriers and Measures of Innovative Drug Entering Health Insurance Directory in China
段晓托 1连桂玉 2贾耀珠1
作者信息
- 1. 沈阳药科大学工商管理学院2014级，沈阳 110016
- 2. 沈阳药科大学工商管理学院，沈阳 110016
- 折叠
摘要
Abstract
OBJECTIVE:To provide a reference for innovative drugs to enter the health insurance directory smoothly and pro-mote the rapid development of pharmaceutical industry in China. METHODS:Based on related policy study of foreign and domes-tic innovative drugs entering the health insurance directory,the policy barriers of innovative drugs entering the health insurance di-rectory were analyzed and the countermeasures were put forward. RESULTS & CONCLUSIONS:In China,the foundation of drug selection was not objective enough;the review results were so vulnerable to subjective views because of the experts selection mech-anism;the health insurance directory deletion mechanism was deficient;the waiting time for innovative drugs entering the health in-surance directory was too long;innovative drugs negotiation mechanism was imperfect,etc. It is recommended that forcibly requir-ing pharmaceutical companies should provid the related data about pharmacoeconomic evaluation;the independence and pluralism of the expert group should be enhanced;drugs in the health insurance directory should be secondarily evaluated regularly;the inno-vative drugs should be given the green channel;innovative drug price negotiation rules should be unified to promote drug informa-tion sharing.关键词
医保目录/创新药/政策Key words
Health insurance directory/Innovative drugs/Policy分类
医药卫生引用本文复制引用
段晓托,连桂玉,贾耀珠..我国创新药进入医保目录的障碍与对策[J].中国药房,2017,28(4):455-457,3.
